Annexon, Inc. Files 8-K Report

Ticker: ANNX · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1528115

Sentiment: neutral

Topics: 8-K, financials, exhibits

TL;DR

Annexon filed an 8-K. Standard financial and exhibit update.

AI Summary

On August 5, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company is based in Brisbane, California, and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates routine corporate reporting by Annexon, Inc. to the SEC, providing transparency for investors regarding its financial and exhibit information.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Annexon, Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on August 5, 2024, as stated in the 'Date of Report (Date of earliest event reported)' field.

What is Annexon, Inc.'s principal executive office address?

Annexon, Inc.'s principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.

What industry does Annexon, Inc. operate in?

Annexon, Inc. operates in the Pharmaceutical Preparations industry, with a Standard Industrial Classification code of [2834].

What is Annexon, Inc.'s telephone number?

Annexon, Inc.'s telephone number, including area code, is (650) 822-5500.

Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-08-05 08:11:59

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 5, 2024, titled "Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy." 104.1 Cover Page Interactive Data File, formatted in inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 5, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing